139,591 Shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 139,591 shares of the company’s stock, valued at approximately $498,000.

Several other large investors have also made changes to their positions in the business. Charles Schwab Investment Management Inc. increased its holdings in Aquestive Therapeutics by 3.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 210,669 shares of the company’s stock valued at $750,000 after acquiring an additional 7,129 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in shares of Aquestive Therapeutics in the fourth quarter worth about $115,000. MONECO Advisors LLC bought a new stake in shares of Aquestive Therapeutics in the fourth quarter worth about $156,000. New York State Common Retirement Fund lifted its position in shares of Aquestive Therapeutics by 713.3% in the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after buying an additional 10,700 shares in the last quarter. Finally, Harvey Capital Management Inc. boosted its stake in Aquestive Therapeutics by 1,419.3% during the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock valued at $952,000 after buying an additional 249,790 shares during the last quarter. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on AQST shares. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Wednesday, April 2nd. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a report on Friday, March 7th. Lake Street Capital dropped their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Finally, Cantor Fitzgerald assumed coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Aquestive Therapeutics has a consensus rating of “Buy” and an average target price of $10.57.

Aquestive Therapeutics Stock Down 3.3 %

AQST stock opened at $2.62 on Tuesday. Aquestive Therapeutics, Inc. has a 52-week low of $2.24 and a 52-week high of $5.80. The company’s 50-day simple moving average is $2.96 and its 200-day simple moving average is $3.85. The firm has a market cap of $259.04 million, a P/E ratio of -5.82 and a beta of 2.59.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $11.87 million for the quarter, compared to analyst estimates of $13.11 million. On average, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.